Search results
This Weird Habit Is One of the Most Common Signs of Brain Cancer, According to Neurologists
Parade· 5 days agoAs scientists try to learn more about brain cancer, it's so important to tune into your body. When...
15 Life-Altering Moments In The Lives Of Cancer Survivors That Will Give You A New Perspective On...
BuzzFeed via Yahoo News· 5 days agoAnton Dobrea / Getty Images 9."I am 78 years old and at the age of 70, I was diagnosed with prostate...
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial -...
Benzinga· 6 days agoThe study did not meet the dual primary endpoints of improvement in overall survival (OS) versus...
Ryne Sandberg reflects on 'love, life, family and friends' as Cubs unveil his statue outside Wrigley...
Chicago Sun-Times· 18 hours agoCubs great Ryne Sandberg set a series of goals when he was diagnosed with metastatic prostate cancer this past winter. “This was a guarantee for me,” Sandberg ...
Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?
Zacks· 7 days agoFree Report) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 33.3% compared with 3.1% growth of the industry. With healthy fundamentals ...
AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study
Zacks via Yahoo Finance· 6 days agoAstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients...
With iOnctura and Yellowstone, Syncona adds two cancer biotechs to growing portfolio
FierceBiotech· 4 days agoSyncona has added two up-and-coming cancer companies to its portfolio, ensuring the biotechs are armed with a combined total of over $100 million in series A and B funds.
Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
BioPharma Dive via Yahoo Finance· 3 days agoA medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two...
IgG4-Related Disease Affects Men More Often, More Severely
Medscape· 5 days agoA recent study highlighted sex-based differences in manifestations of IgG4-related disease.
FDA Expands Orphan Drug Designation for SurVaxM, I | Newswise
Newswise· 4 days agoBUFFALO, N.Y. — The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park ...